{"id":"https://openalex.org/W2094969552","doi":"https://doi.org/10.1007/s00280-004-0832-z","title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","display_name":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","publication_year":2004,"publication_date":"2004-05-07","ids":{"openalex":"https://openalex.org/W2094969552","doi":"https://doi.org/10.1007/s00280-004-0832-z","mag":"2094969552","pmid":"https://pubmed.ncbi.nlm.nih.gov/15138710"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-004-0832-z","doi":"https://doi.org/10.1007/s00280-004-0832-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-004-0832-z","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026261845","display_name":"Catherine Dutreix","orcid":"https://orcid.org/0009-0000-0851-3423","observed_orcids":["https://orcid.org/0009-0000-0851-3423"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Catherine Dutreix","raw_affiliation_strings":["Novartis Pharma AG, 4002 Basel, Switzerland. catherine.dutreix@pharma.novartis.com","Novartis Pharma AG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, 4002 Basel, Switzerland. catherine.dutreix@pharma.novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100642759","display_name":"Bin Peng","orcid":"https://orcid.org/0000-0001-5211-1544","observed_orcids":["https://orcid.org/0000-0001-5211-1544"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bin Peng","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","Novartis Pharmaceuticals Corporation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033148582","display_name":"Guenther H. Mehring","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Guenther Mehring","raw_affiliation_strings":["Novartis Pharma AG, 4002, Basel, Switzerland","Novartis Pharma AG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, 4002, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011431249","display_name":"Michael Hayes","orcid":"https://orcid.org/0000-0002-9215-1484","observed_orcids":["https://orcid.org/0000-0002-9215-1484"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Hayes","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","Novartis Pharmaceuticals Corporation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022108188","display_name":"Renaud Capdeville","orcid":"https://orcid.org/0000-0001-7611-0765","observed_orcids":["https://orcid.org/0000-0001-7611-0765"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Renaud Capdeville","raw_affiliation_strings":["Novartis Pharma AG, 4002, Basel, Switzerland","Novartis Pharma AG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, 4002, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087154649","display_name":"Rolf Pokorny","orcid":"https://orcid.org/0000-0002-3681-6007","observed_orcids":["https://orcid.org/0000-0002-3681-6007"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rolf Pokorny","raw_affiliation_strings":["Swiss Pharma Contract Ltd, Allschwil, Switzerland","Swiss Pharma Contract Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swiss Pharma Contract Ltd, Allschwil, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Swiss Pharma Contract Ltd","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044662094","display_name":"Michael Seiberling","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Seiberling","raw_affiliation_strings":["Swiss Pharma Contract Ltd, Allschwil, Switzerland","Swiss Pharma Contract Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Swiss Pharma Contract Ltd, Allschwil, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Swiss Pharma Contract Ltd","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5026261845"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":4.0681,"has_fulltext":false,"cited_by_count":157,"citation_normalized_percentile":{"value":0.94321589,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"54","issue":"4","first_page":"290","last_page":"4"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8360000252723694},{"id":"https://openalex.org/keywords/ketoconazole","display_name":"ketoconazole","score":0.9700000286102295},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8529999852180481},{"id":"https://openalex.org/keywords/cyp3a4-inhibition","display_name":"CYP3A4 inhibition","score":0.9350000023841858},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7360000014305115},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.42100000381469727},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.6449999809265137},{"id":"https://openalex.org/keywords/crossover-design","display_name":"crossover design","score":0.5080000162124634},{"id":"https://openalex.org/keywords/enzyme-inhibition","display_name":"enzyme inhibition","score":0.4189999997615814},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7250000238418579},{"id":"https://openalex.org/keywords/lc-ms-ms","display_name":"LC-MS/MS","score":0.6919999718666077}],"concepts":[{"id":"https://openalex.org/C2781064554","wikidata":"https://www.wikidata.org/wiki/Q407883","display_name":"Ketoconazole","level":3,"score":0.9320666790008545},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8626031279563904},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7140683531761169},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.6376521587371826},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6128673553466797},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.6026171445846558},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.577369213104248},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5442256927490234},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.525315523147583},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.5245882868766785},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4496394693851471},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4416257441043854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3410514295101166},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.0652921199798584},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.05586665868759155},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.0},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007654","descriptor_name":"Ketoconazole","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007654","descriptor_name":"Ketoconazole","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-004-0832-z","doi":"https://doi.org/10.1007/s00280-004-0832-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-004-0832-z","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:15138710","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15138710","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":25,"referenced_works":["https://openalex.org/W1490860457","https://openalex.org/W1581407744","https://openalex.org/W1991417422","https://openalex.org/W2003278476","https://openalex.org/W2015015957","https://openalex.org/W2017021967","https://openalex.org/W2028959752","https://openalex.org/W2049697220","https://openalex.org/W2050450820","https://openalex.org/W2058387955","https://openalex.org/W2068639674","https://openalex.org/W2076565275","https://openalex.org/W2079446921","https://openalex.org/W2079517811","https://openalex.org/W2085192147","https://openalex.org/W2095974037","https://openalex.org/W2120033838","https://openalex.org/W2134094496","https://openalex.org/W2142969636","https://openalex.org/W2151504205","https://openalex.org/W2151968496","https://openalex.org/W2154169171","https://openalex.org/W2158774273","https://openalex.org/W2171722798","https://openalex.org/W2329648702"],"related_works":["https://openalex.org/W1985758966","https://openalex.org/W4255859061","https://openalex.org/W7222761129","https://openalex.org/W2031789773","https://openalex.org/W2068639674","https://openalex.org/W2163974352","https://openalex.org/W2603056439","https://openalex.org/W2537110585","https://openalex.org/W4405763452","https://openalex.org/W2143613482"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":15},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}